disitamab vedotin + S-1 + xindilizumab

Disitamab vedotin + S‑1 + xindilizumab is a combination regimen under investigation for the treatment of advanced HER2-overexpressing gastric and gastroesophageal junction cancers. Disitamab vedotin is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), consisting of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E via a cleavable linker. It binds to HER2 on tumor cells, is internalized, and releases MMAE intracellularly to disrupt microtubules and induce cell death[1][2][4]. S‑1 is an oral fluoropyrimidine-based chemotherapy combining tegafur with modulators gimeracil and oteracil, designed to enhance antitumor activity while reducing gastrointestinal toxicity. Xindilizumab is a monoclonal antibody immune checkpoint inhibitor targeting PD‑1, enhancing T-cell mediated antitumor immunity. The combination aims to leverage targeted cytotoxicity, chemotherapy-induced tumor cell kill, and immune activation for synergistic efficacy in HER2-positive cancers[3].

Brand names

Aidixi (for disitamab vedotin)

Other names

爱地希 (for disitamab vedotin)RC48 (for disitamab vedotin)